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Abstract
Epithelial to mesenchymal transition (EMT) not only occurs during embryonic development and in response to injury, but is
an important element in cancer progression. EMT and its reverse process, mesenchymal to epithelial transition (MET) is
controlled by a network of transcriptional regulators and can be influenced by posttranscriptional and posttranslational
modifications. EMT/MET involves many effectors that can activate and repress these transitions, often yielding a spectrum of
cell phenotypes. Recent studies have shown that the miR-200 family and the transcriptional suppressor ZEB1 are important
contributors to EMT. Our previous data showed that forced expression of SPRR2a was a powerful inducer of EMT and
supports the findings by others that SPRR gene members are highly upregulated during epithelial remodeling in a variety of
organs. Here, using SPRR2a cells, we characterize the role of acetyltransferases on the microRNA-200c/141 promoter and
their effect on the epithelial/mesenchymal status of the cells. We show that the deacetylase inhibitor TSA as well as P300
and PCAF can cause a shift towards epithelial characteristics in HUCCT-1-SPRR2a cells. We demonstrate that both P300 and
PCAF act as cofactors for ZEB1, forming a P300/PCAF/ZEB1 complex on the miR200c/141 promoter. This binding results in
lysine acetylation of ZEB1 and a release of ZEB1 suppression on miR-200c/141 transcription. Furthermore, disruption of P300
and PCAF interactions dramatically down regulates miR-200c/141 promoter activity, indicating a PCAF/P300 cooperative
function in regulating the transcriptional suppressor/activator role of ZEB1. These data demonstrate a novel mechanism of
miRNA regulation in mediating cell phenotype.
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Introduction
The KAT3 histone acetyltransferases CREB binding protein
(CBP) and P300 have at least 400 interacting protein partners,
thereby acting as hubs in gene regulatory networks [1]. They are
transcriptional co-activators for various sequence-specific tran-
scription factors and play a broad biological role in cell cycle
regulation, proliferation, differentiation, apoptosis, DNA damage
repair, adhesion, carcinogenesis, and embryonic development
[2,3]. These molecules act primarily through acetylation of
histones and other regulatory proteins (e.g. p53). Moreover,
several studies suggest that disruption of P300/CBP occurs in
many human diseases including cancer [4], inflammatory lung
diseases [5], and viral infections [6]. These associations with
human disease make P300/CBP attractive therapeutic targets.
In cancer biology, P300 is thought to be an anti-cancer gene [4]:
the potential of P300 to inhibit cancer progression is linked to
phenotype control, such as epithelial-mesenchymal transition
(EMT). In a colon carcinoma cell line, loss of P300 induced
EMT and resulted in aggressive cell migration [7]. In another
study, the downstream effector of P300, CITED2, was shown to
reduce matrix metalloproteinase-13 and inhibit cell growth in the
colon carcinoma cell line RKO [8]. The underlying mechanisms,
however, in these P300 anti-cancer effects need to be elucidated.
During EMT, cells acquire stem cell-like properties such as
migration, invasiveness, loss of apoptosis and senescence, and
immunosuppression [9]. A number of growth factors, including
transforming growth factor-beta, and their downstream effectors,
such as Ras and Src, are involved in EMT [9]. Loss of miR-200
family member (miR-200a,b,c, miR-141, and miR-429) expression
and up-regulation of ZEB1 and ZEB2 are other important
contributors to EMT [10,11,12].
Expression levels of miR-200 family members and ZEB1/ZEB2
are closely and inversely associated. miR-200 down-regulates the
expression of the transcription factors ZEB1 and ZEB2 by binding
to the 39 untranslated region of the mRNA and preventing
translation. Conversely, transcription of both miR-200 clusters,
one on chromosome 1 and the other on chromosome 12, are
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negatively regulated by ZEB1 or ZEB2 binding to the E-box of the
miR promoter [10,11,12]. The miR-200 family has also been
described as being dysregulated during cancer progression [10,13],
and more importantly, this occurs in a stage specific manner [14].
The early stage of metastasis is similar to EMT, but later,
following extravasation, metastasizing cells settle in target tissue
and undergo differentiation processes that involve mesenchymal to
epithelial transition (MET) [15]. According to this scenario, when
cancer cells become invasive (EMT) miR-200 may be downreg-
ulated, but during re-epithelialization of distal metastases (MET)
miR-200 may be upregulated. This strongly suggests that tumor
cell phenotype can be malleable, possibly responsive to environ-
mental cues. Understanding how miR-200 family expression is
controlled during these processes, and how its expression affects
phenotype, can yield clarification of cancer progression as well as
potential therapeutic targets.
To address these questions, we generated an in vitro model of
EMT, obtained by stable transfection of HuCCT-1 cholangiocarci-
noma cells with one of the epidermal differentiation complex genes,
small proline rich protein (SPRR) 2a. Over expression of SPRR2a
causes HuCCT-1 cells to undergo EMT, as indicated by loss of E-
cadherin, upregulation of vimentin, induction of cell motility and a
change in cell morphology [16]. While investigating SPRR2a-
induced EMT, we found that acetylation enhanced miR200c
transcription and moderated expression levels of some EMT
markers in our stable transfectants. We show that the acetyltrans-
ferases P300 and PCAF activate miR200c/141 transcription by
interacting at its promoter region via the cysteine-histidine rich
(CH3) domain of P300. Furthermore, these acetyltransferases
overcome ZEB1 transcriptional suppression of miR200c, most
likely through lysine acetylation of ZEB1. Our data shows the
importance of the CH3 domain of P300 in regulating miR200c
expression and the relationship to epithelial/mesenchymal status.
Materials and Methods
Mice, cultured cells, and SPRR2a stable transfectants
The human intrahepatic cholangiocarcinoma cell line HuCCT-
1 was cultured as described [10,17]. To evaluate the effects of
SPRR2a expression, we made stable transfectants with a SPRR2a
expressing vector as previously reported [16]. The negative control
was a stable transfectant containing the vacant vector.
TGF-b1, TSA/AZA, and PP2 treatment of cells
Cells were plated and cultured for 24 hours prior to treatment
with 1 mg/ml of 5Aza-dC(AZA) (Sigma, St. Louis, MO) or 1 ug/
ml of Trichostatin A (TSA) (Sigma) for 48 hours [18]. For the
combination AZA/TSA, cells were dosed first with 1 ug/ml of
AZA for 24 hr followed by treatment with 1 ug/ml of TSA for an
additional 24 hr. For TGF-b1 treatment, cells were plated for 8–
12 hours, washed with PBS and incubated in serum free medium
(SFM) for 8 hrs. Recombinant human TGF-beta1 (5 ng/ml,
R&D, Minneapolis, MN) was added to the SFM and cells
incubated for an additional 24 hrs. Finally, sub-confluent 24 hour
cell cultures were treated with 20 mM PP2 (Calbiochem, San
Diego, CA) for designated times.
siRNA, Pre-miR and anti-miR transfections
Cultured cells were transfected with: target specific (ABL1;
Assay ID s866, EP300; Assay ID s4696,) or negative control
SilencerH Select siRNA; precursor hsa-miR-200c and hsa-miR-
141 (ID: PM11714; PM10860); Anti-miRTM 200c and 141
inhibitors (ID: MH11714; MH10860) (Ambion, Austin, TX) for
8 hours in serum free medium. Serum supplemented medium was
added and gene and protein expression measured at the indicated
time points.
Biotinylated oligonucleotide precipitation Assays
The assays were carried out as described [19]. Briefly, 24 hours
after transfection, cells were lysed with HKMG buffer (10 mM
HEPES, pH 7.9, 100 mM KCl, 5 mM MgCl2, 10% glycerol,
1 mM DTT, and 0.5% of NP-40) containing protease and
phosphatase inhibitors. Extracted proteins were pre-cleared with
ImmunoPure streptavidin-agarose beads (Pierce, Rockford, IL) for
1 hr. Pre-cleared lysates were then incubated 12 hours with 1 mg
of the 59-biotinylated double-stranded oligonucleotides and 10 mg
of competitor DNA (poly (dI-dC).poly(dI-dC) to eliminate non-
specific protein/DNA interactions. Oligo-specific bound proteins
were collected with streptavidin-agarose beads and separated by
SDS-PAGE. Protein identification was done by Western blotting.
Transfection and luciferase reporter assay
Transfections with DNA plasmids and siRNA molecules were
done with Lipofectamine 2000 (Invitrogen, Carlsbad, CA) and
with Lipofectamine RNAiMAX (Invitrogen), respectively, accord-
ing to the manufacturer’s instructions. Luciferase assays were
carried out with a Promega (Madison, WI) assay kit system and
measured on a luminometer.
Western blotting and Immunoprecipitation
For Western blotting, cell lysates were obtained using TNE
buffer (50 mM Tris pH 8.0, 150 mM NaCl, 10% v/v NP40,
2 mM EDTA) containing protease inhibitors. All protein concen-
trations were measured using a BCA Protein Assay kit (Pierce).
Proteins were separated by SDS-PAGE, transferred to nitrocellu-
lose membranes, and blocked with 5% skim milk in TBST (Tris-
buffered Saline Tween-20). Standard immunostaining was carried
out using enhanced chemiluminescence reagents (Pierce).
For immunoprecipitation, TNE cell lysates were incubated with
appropriate antibodies and the protein/antibody complexes
collected using protein G Dynabeads (Invitrogen). Immunopre-
cipitated proteins were identified by Western blotting. The
antibodies used in this study are as follows: anti-HA antibody (F-
7, Santa Cruz, Santa Cruz, CA); anti-P300 antibody (N-15, Sata
Cruz); anti-ZEB1 antibody (H102, Santa Cruz); anti-PCAF
(C14G9, Cell Signaling Technology, Danvers, MA); anti-acetyl-
ated lysine (9441, Cell Signaling Technology); anti-Flag (M2,
Sigma); anti-S100A4 (X9-7, Santa Cruz); anti-vimentin (BioVi-
sion, Mountain View, CA); anti-E-cadherin (36, BD Biosciences,
Bedford, MA); anti-V5 (Invitrogen)
Immunostaining
Cells were cultured on glass coverslips and transfected with
appropriate agents as described above. At the designated time
point cells were fixed for 1 hour in 1% paraformaldehyde prior to
staining. Primary antibody: E-cadherin (listed above); secondary
antibody: biotinylated horse anti-mouse (Vector Laboratories,
Burlingame, CA). Fluorescence was obtained using streptavidin
conjugated QdotsH (Invitrogen).
RNA and genomic DNA extraction, PCR, and real-time
PCR
Total RNA was extracted using Trizol (Invitrogen) according to
the manufacturer’s instructions. Reverse transcription was per-
formed using a High Capacity cDNA reverse transcription kit
(Applied Biosystems, Foster City, CA) and random primers. Total
genomic DNA was extracted using PureLink Genomic DNA Mini
P300 and PCAF Control miR 141/200c Transcription
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Kit (Invitrogen). To amplify the target genes, PCR reactions were
performed with EX Taq Hot Start polymerase (Takara Bio Inc,
Otsu, Shiga, Japan). PCR products were analyzed on 12%
polyacrylamide gels and visualized using ethidium bromide. Gene
expression of mRNA, primary-miRNA, and precursor- miRNA
were quantified by SYBR Green or TaqMan real-time PCR using
specific primers. The real-time SYBR Green PCR primers were
designed using Primer 3 software and are as follows: pri-141/
200C, for- AGGGAAGGGGTTAAGGCAGT and rev- GAG-
GTGCCTAGGGAACCAGT; E-cadherin, for- CCCACCACG-
TACAAGGGTC and rev- CTGGGGTATTGGGGGCATC;
MLH, for- ACAGCTGATGGAAAGTGTGCAT and rev- AT-
TGCCAGCACATGGTTTAGG; GAPDH, for- ACAGTCAG-
CCGCATCTTCTT and rev- ACGACCAAATCCGTTGACT-
C; S100A4, for- GATGAGCAACTTGGACAGCA and rev- CT-
TCCTGGGCTGCTTATCTG. Expression was normalized to
GAPDH using the comparative 2-DDCT method. TaqMan primers
were used to quantify miRNA, vimentin, ZEB1 and ABL1 expression.
miRNA expression was normalized to U6 snRNA and mRNA to
GAPDH using the comparative 2-DDCT method (Applied Biosys-
tems: miR-200c, 002300; miR-141, 000436; miR-200b, 002251;
miR-429, 001024; U6, 001973; GAPDH, 4310884E; ABL1,
Hs01104728; VIM, Hs00185584; ZEB1, Hs00232783)
Plasmids
The human SPRR2a expression vector (pTracer) (Invitrogen)
which has a C-terminal His-V5-tag was constructed as described
before [16]. Human HA-tagged P300 and its CH3 deletion
protein expression vectors and the Flag-tagged PCAF vector were
purchased from Addgene (Cambridge, MA). The human Halo-
tagged ZEB1 vector was obtained from Promega (Madison, WI).
The 2126/152 miR-200c/141 promoter construct was generated
by PCR according to previous reports [12], and subcloned into a
pGL3 vector (Promega).
Statistics
All statistical analyses were performed using SigmaStat software.
A P value of ,0.05 was considered statistically significant, and all
tests were two-tailed. All interval values are expressed as mean 6
SD. Comparison between two groups was performed using the
unpaired Student t-test. And comparison among three or more
groups was performed using a one-way ANOVA.
Results and Discussion
Deacetylase inhibitor TSA can enhance expression of
some Epithelial Markers in SPRR2a Cells
SPRR2a induction of EMT fully converts cells from an
epithelial to mesenchymal status, as evidenced by gross
morphological changes, loss of E-cadherin and upregulation of
vimentin (Figure 1A). In addition, expression of the miRNA-200
family is strongly inhibited in HuCCT-1 SPRR2a cells, especially
miR-200c (Figure 1B). Both clusters of the miRNA 200 family
are polycistronic transcripts coded on chromosome 12 (miR-
200c/141) and chromosome 1 (miR-200b/a/429) [10,11]. The
promoter region of miR-200b/a/429 has a CpG island, whereas
miR-200c/141 does not [11]. Because SPRR2a can act as a SH3
ligand for Src-family kinases and Abl-family kinases, and
SPRR2a expression results in Src activation (418Tyr phosphor-
ylation) [16], we hypothesized that SH3 domain containing
tyrosine kinases might play a role in SPRR2a induced EMT.
Therefore, we first examined the effect of siRNA molecules
targeting ABL1 on miRNA-200c expression in HuCCT-1-
SPRR2a cells (Fig. 1B). Since this did not affect miR200c or
miR200b expression, we next examined the effect of a more
global tyrosine kinase inhibitor, PP2, with the expectation that
PP2 would increase miR-200c and shift cells towards an epithelial
phenotype. Real-time PCR analysis showed that PP2 does not
affect miRNA-200c levels (Figure 1C).
We next tested whether the acetylation and/or methylation
status were important in controlling miR-200 family expression by
treating SPRR2a cells with the histone deacetylase inhibitor,
Trichostatin A (TSA), and the methyltransferase inhibitor, 5-aza-
29-deoxycytidine (AZA). Individually, these agents are used to
determine the relevance of acetylation or de-methylation in gene
expression. If used together, TSA and AZA often yield
Figure 1. EMT induced by SPRR2a in HuCCT-1 involves loss of E-cadherin, increased vimentin, and reduction of miR-200 family
transcription as compared to vector transfected controls. Examples of the morphological changes and changes in E-cadherin and vimentin
expression in stable SPRR2a clones (NC=negative control) (A). Transcriptional loss of the miR200 family in SPRR2a expressing cells does not involve
SH3 domain containing tyrosine kinases. Real-time PCR analysis of miR-200 family after 72 hrs treatment with ABL1 siRNA (B) and PP2 treatment (C)
did not alter miR-200 expression. All clones used in this paper stably express SPRR2a (D). Real time PCR analysis: comparative 2-DDCT method
(miRNA: U6 internal control; ABL1: GAPDH internal control). (n = 2 independent experiments).
doi:10.1371/journal.pone.0032449.g001
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Figure 2. In mesenchymal HuCCT-1 SPRR2a cells, acetylation can cause epithelial shifts in miR200c/141, vimentin and Zeb1
expression. De-methylation has less impact on miR200c/141 transcription, but does affect EMT marker protein expression. In HuCCT-1 SPRR2a cells,
TSA yields a greater epithelial shift in miR200c/141 expression than AZA, while miR200b/a/429 is unaffected (A). TSA increased expression levels for
both primary miR-200c/141 and premature miR-200c transcripts as well (A). The efficacy of TSA/AZA treatment was monitored by western blot for
acetylated lysine (TSA) and real time PCR for MLH expression (AZA) (A). Expression levels of EMT markers (both mRNA and protein) showed that TSA
also reduced expression of vimentin and Zeb1 in SPRR2a cells (partial MET shift), while AZA treatment increased expression of all markers tested (B).
Finally, SPRR2a over expression was maintained during TSA/AZA treatment (B). Real time PCR analysis: comparative 22DDCT method (U6 or GAPDH
P300 and PCAF Control miR 141/200c Transcription
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transcriptional synergistic effects, a tool frequently employed to
unmask epigenetically silenced genes in malignancies. Acetylated
histones lose their charge, enabling DNA unwinding, and
unmethylated DNA allows transcription factors easier access to
promoter regions. In combination, they remove major conforma-
tional impediments to gene transcription.
Treatment of SPRR2a expressing cells with TSA significantly
increases expression levels of miR-200c and miR-141, but had
little effect on miR429/200b (Figure 2A). To confirm that TSA
is activating miR-200c transcription, we show a similar increase
in expression levels for both primary miR-200c/141 and
premature miR-200c transcripts (Figure 2A). SPRR2a cells
show some increase in miR200c/141 expression after AZA
treatment as well, indicating that this gene is also regulated in
part by DNA methylation [20]. However, the impact on
miR200c/141 transcription was greater following TSA treat-
ment. The efficacy of our treatments was monitored by
examining changes in lysine acetylation after TSA via western
blot and by measuring MLH gene expression after AZA
treatment, a gene whose expression is known to be controlled
through methylation [18] (Figure 2A).
Since TSA and AZA partially recovered epithelial miR200c
expression, we then examined their influence on expression of
downstream EMT-associated genes. SPRR2a induced EMT in
HuCCT-1 cells correlates with changes in E-cadherin, ZEB1,
vimentin, and S100A4 expression, while other EMT-associated
genes such as TWIST or SNAIL remain unchanged (gene array
and real time PCR; data not shown). Concordant with TSA
reversal of miR-200c expression, there was significant down
regulation of ZEB1 and vimentin (MET changes). E-Cadherin and
S100A4 expression levels did not significantly change (Figure 2B),
but the observed trends were in the expected direction.
EMT/MET is a complex process. SPRR2a induction causes
changes in morphology and staining intensities (Figure 1) that
represent both phenotypic extremes: an epithelial (vector) or
mesenchymal (SPRR2a clone) state, both of which correlates with
the expression levels of important molecules as measured by PCR
and western blots (Figure 2). Our interpretation of changes in the
mRNA and protein levels following cell treatments represent the
extent of epithelial/mesenchymal shift. Transitioning from an
epithelial to mesenchymal (and visa-versa) phenotype is not an all-
or-nothing event, but instead, occurs along a continuum in
response to the level of signals, factors and co-factors within the
cell [21]. Consequently, TSA contributes to MET changes in
SPRR2a cells (increased miR200c; decreased Vimentin and
ZEB1), but not to the same extent seen in the vector cells and
alone was unable to completely reverse the gross (visible) cell
phenotype (data not shown). This data does, however, emphasize
the role of acetylation in regulation of miR200c, ZEB1 and VIM.
Lastly, AZA treatment increased expression of all genes tested in
Figure 2B, indicating that expression levels for these genes (E-
CAD, VIM, S100A4, ZEB1) can be regulated by CpG
methylation.
To verify that the response to TSA and AZA in our SPRR2a
cells was not due to a clonal effect, we measured miR200c, E-
cadherin and vimentin in two other SPRR2a stable transfectants
and observed similar responses. In addition, SPRR2a expression
was maintained in the clones during treatments, indicating that the
results were not attributable to loss of SPRR2a expression. If
anything, TSA slightly increased SPRR2a expression.
P300/PCAF activate miR-200c/141 promoter
CBP/P300 participate in transcriptional control by: 1)
bridging gene-specific transcription factors with the basic
transcriptional component, 2) contributing to the formation of
multi-protein complexes and modulating the activation status of
gene-specific transcription factors through post-translational
modifications and 3) exhibiting acetyl-transferase activity on
nucleosomes and certain gene-specific transcription factors.
Using a miR-200c/141 promoter construct, which includes the
E-box and Z-box elements (Figure 3A), we found that TSA
treatment enhanced promoter activity (Figure 3B). This
observation suggests that some proteins that bind to the
promoter region are acetylated and this acetylation increases
miR-200c/141 promoter activity.
One such candidate protein is ZEB1. ZEB1 is involved in
transcriptional control of a number of key regulatory genes
involved in differentiation and development [22]. ZEB1 can act
as a transcriptional repressor through recruitment of the co-
repressor, C-terminal binding protein (CtBP) [23]. However,
transcriptional activation of the vitamin D3 receptor and the
estrogen-responsive ovalbumin gene by ZEB1 occurred after
recruitment of P300 and PCAF to the ZEB1 binding site [24].
Binding of PCAF to ZEB1 acetylates several lysine residues close
to the CtBP interacting domain of ZEB1, displacing CtBP and
switching ZEB1 from a transcriptional repressor to an activator
[24]. On the miR-200c/141 promoter, ZEB1 binding to the E-
box and Z-box elements suppresses transcriptional activity [12].
Since ZEB1 binds the miR-200c/141 promoter and TSA-
induced acetylation enhanced promoter activity, we investigated
what role the acetyltransferases P300 and PCAF might have on
transcription of the miR-200c/141 promoter. HuCCT-1-
SPRR2a cells (low miR-200c/141; high ZEB1) transfected with
a P300 vector show increasing promoter activity in a dose-
dependent manner (Figure 3C). In parent HuCCT-1 cells (high
miR-200c/141; low ZEB1), transfection of a ZEB1 expressing
vector significantly inhibited the promoter activity, but high dose
co-transfection with a P300 vector significantly antagonized the
ZEB1-induced suppression (Figure 3D). A similar effect was also
observed in HuCCT-1 parent cells transfected with ZEB1 and
PCAF expression vectors (Figure 3E), indicating that both P300
and PCAF can activate the miR-200c/141 promoter, probably
through acetylation of ZEB1. Moreover, in parent HuCCT-1
cells, co-transfection with a SPRR2a vector could significantly
antagonize P300 induced promoter activation (Figure 3F). This
observation supports an opposing function for P300/PCAF and
SPRR2a in affecting miR-200c/141 transcription in HuCCT-1
cells.
P300/PCAF complexes with and acetylates ZEB1 on the
miR-200c/141 promoter to activate transcription
Co-immunoprecipitation of ZEB1 and P300 was seen in
HuCCT-1 cells transfected with a HA- tagged P300 vector. In
addition, less ZEB1 co-immunoprecipitates when a CH3 deleted
P300 vector is used, indicating a role for the CH3 region during
ZEB1/P300 interactions. Likewise, PCAF/P300 complexes were
internal control) and expression levels for HuCCT-1-vector cells were set to 1.0. (n$3 independent experiments; *, P,0.05; **, P,0.01; ***,P,0.005;
Student’s t-test).
doi:10.1371/journal.pone.0032449.g002
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Figure 3. P300 and PCAF activate the miR-200c/141 promoter, while ZEB1 and SPRR2a inhibit this activation. Illustration of miR-200c/
141 promoter, E-box, Z-box, and transcription starting site (TSS) as well as miR-200c/141-luciferase vector and DNA-pull down assay probes (A).
Luciferase assay for miR-200c/141-promoter activity in SPRR2a expressing cells: Treatment with TSA and/or AZA shows TSA increased promoter
activity (B), as did transfection with a P300 expression vector (0, 0.05, 0.1, 0.2, 0.4 mg) (C). Luciferase assay for miR-200c/141-promoter activity in
HuCCT-1 parent cells: transfection with a ZEB1 expression vector (0.1 mg) reduced miR-200c/141-promoter activity, while co-transfection with P300
(0,0.05, 0.1, 0.2, 0.4 mg) (D) or PCAF (0, 0.1, 0.2, 0.4 mg) (E) antagonized this repression. In contrast, transfection with a P300 expression vector (0.4 mg)
P300 and PCAF Control miR 141/200c Transcription
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verified in HuCCT-1 cells transfected with a PCAF vector and
immunoprecipitated using a P300-specific antibody. Finally, this
binding of P300/PCAF/ZEB1 is not affected by TGF- b1, as was
seen in a previous report [24] (Figure 4A).
HuCCT-1 cells, transfected with both PCAF and ZEB1
expressing vectors, show acetylation of lysine residues on ZEB1,
whereas cells transfected with only ZEB1 have no lysine
acetylation (Figure 4B). This observation is in accordance with
a previous report [24]. To further investigate whether these
interactions directly contribute to miRNA 200c/141 transcription,
we constructed biotinylated double-stranded oligonucleotide
probes that mimic the wild type or mutational sequences in the
E-box and Z-box binding sites for ZEB1 (Figure 3A). Lysates
from cells are incubated with the biotinylated DNA sequences and
the resulting complexes precipitated with strept-avidin beads.
Precipitating proteins are then visualized via western blot using
enhanced miR-200c/141-promoter activity, while co-transfection with SPRR2a (0,0.05, 0.1, 0.2, 0.4 mg) negated this effect (F). (Data represents 2–3
independent experiments; *, P,0.05; **, P,0.01; ***, P,0.001; (B) Student’s t-test; (C–F) one-way ANOVA).
doi:10.1371/journal.pone.0032449.g003
Figure 4. P300/PCAF complexes with ZEB1 on the miR-200c/141 promoter and requires the CH3 domain of P300 for transcription.
Immunoprecipitation of P300 following transfection with the indicated protein expression vectors verifies P300/ZEB1 and P300/PCAF interactions,
which were unaffected by TGF-b1 treatments (5 ng/mL; 24 hrs) (A). Immunoprecipitation experiments show PCAF acetylates ZEB1 following
transfection with ZEB1 6 PCAF expression vectors (24 hrs) (B). DNA pull-down assay using a wild type (wt) or mutational E-box/Z-box sequence for
the miR-200c/141 promoter after co-transfection of HuCCT-1 shows binding of ZEB1 and PCAF to the wt promoter sequence (C), and p300/PCAF/
ZEB1 binding to the wt promoter, which is unaffected by TGF-b1 treatments (5 ng/mL; 24 hrs) (D). Luciferase assay for miR-200c/141 promoter
activity following transfection with wild type or CH3 deleted P300 expression vector in HuCCT-1 parent cells shows the CH3 domain is required for
miR transcription. (n = 3 independent experiments; ***, P,0.001; Student’s t -test) (E).
doi:10.1371/journal.pone.0032449.g004
P300 and PCAF Control miR 141/200c Transcription
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appropriate antibodies. Lysates from HuCCT-1 parent cells,
which were co-transfected with PCAF and ZEB1 expression
vectors, show that ZEB1 and PCAF can only complex to promoter
sequences with intact, wild type E-box/Z-box elements
(Figure 4C). Moreover, P300 is also a component of the
ZEB1/PCAF complex on the promoter (Figure 4D). A previous
report showed ZEB1 switches from a transcriptional repressor to a
co-activator in response to TGF-b1treatment [24]. In our cells,
however, binding of P300/PCAF/ZEB1 is not affected by
treatment with TGF beta1 (Figure 4A and 4D).
The CH3 region of P300 is required for miR-200c/141
promoter activity
CBP and P300 were originally identified as factors binding to
the cAMP response element-binding protein (CREB) [25] and the
adenovirus E1A associated protein [26]. Numerous reports
demonstrate that CBP/P300 have specific areas that allow for
interactions with a wide array of transcription factors and co-
factors [27]. The cysteine and histidine-rich region 3 (CH3) of
P300 is one site for interaction with many transcription factors,
including the adenovirus E1A oncoprotein, the co-activator PCAF
and the SV40 large T antigen [26] [28,29]. As shown in
Figure 4E, transfection with a CH3-deleted P300 vector
dramatically suppressed the activity of our luciferase miR-200c/
141 promoter construct when compared to transfection with wild
type P300. Without the CH3 region, there is less interaction
between P300 and PCAF and reduced miR-200c/141 promoter
activity. Also, immunoprecipitation of HuCCT-1-parent cells
transfected with a CH3 deleted P300 vector (Figure 4A) yielded
less ZEB1, indicating that P300 may need PCAF binding to fully
interact with ZEB1.
Changes in miR200c/141 and P300 can shift EMT marker
expression
First, to demonstrate the prominent role miR200c/141 has on
the epithelial/mesenchymal state in HuCCT-1 cells, we mea-
sured how inhibition and overexpression of these miRNA
changed EMT marker expression. Since miR200c/141 is
transcribed en-block [11], we knocked down expression by
transfection with dual inhibitors (Anti-miRTM 200c and 141).
Successful inhibition was verified by monitoring target gene
(ZEB1) expression. Inhibition of miR200c/141 yielded a partial
EMT conversion in the vector cells, as evidenced by increased
ZEB1 and vimentin accompanied by a phenotypic change
(Figure 5A). This phenotypic change appears to be matrix
dependent, as it was only observed when cells were grown on
glass coverslips and not on tissue culture plastic. Despite these
changes, vector cell E-cadherin expression was unaffected by the
inhibitors. Real time PCR analysis correlates the changes seen in
vector protein with mRNA levels (Figure 5A).
In a reverse experiment, dual transfection with pre-miR-200c
and pre-miR-141 caused an MET shift in SPRR2a expressing
cells. A significant phenotypic conversion was accompanied by an
increase in E-cadherin expression (protein and mRNA), with
localization along cell-cell borders. However, no changes in
vimentin expression were observed (Figure 5B). Increases in
mature miR-200c and miR-141 transcripts in both cell lines
verified successful transfection with pre-miR species (Figure 5B).
EMT shifts in vector cells (Figure 5A) and MET shifts in
SPRR2a cells (Figure 5B) verifie the central role of miR200c/141
in modulating cell phenotype. Alone, these agents caused
significant changes in vimentin, E-cadherin, miR200c, and gross
phenotype, depending on the direction of the transition, but not all
4 parameters changed simultaneously. This observation substan-
tiates the viewpoint that EMT/MET is a complex process and
cellular transition from one state to the other encompasses a
continuum of phenotypes involving many effectors.
The role of P300 in EMT is controversial. Some show high
P300 expression leads to EMT [30], while others show P3002/2
cells undergo EMT [7]; the differences might be contextual [1].
Since we showed that P300 forms a complex (P300/PCAF/
ZEB1) on the miR200c promoter, resulting in lysine acetylation
of ZEB1 and transcriptional activation of miR200c, we expected
that knockdown of P300 would lead to a more mesenchymal
phenotype (EMT shift) in our cells. As seen in Figure 5C,
SPRR2a expression does not affect endogenous P300 protein
levels. In our cells, P300 siRNA treatment yielded a significant
decrease in miR200c expression for the vector cells (EMT shift).
This is most likely due to a corresponding decrease in p300
mediated acetylation of ZEB1 on the miR promoter. Also, P300
siRNA did not significantly affect E-cadherin expression in the
vector cells, but did decrease it in the SPRR2a clone (an EMT
shift). P300 is a transcriptional co-activator that also binds to the
promoter region of E-cadherin and enhances gene expression
[31]. Reduced E-cadherin in the clone, but not the vector cells,
suggests that SPRR2a over expression may affect the intrinsic
acetyltransferase activity of P300 (an area for future study).
Finally, vimentin expression was unchanged in the SPRR2A
clone, but it unexpectedly decreased in the vector control. This
suggests that P300 is not essential for maintenance of vimentin
expression during SPRR2a EMT, but may affect gene
expression in the epithelial state. Although P300 is involved
with transcriptional control of miR200c, inhibition of this co-
factor alone was insufficient to cause a phenotypic shift in our
cells.
Transcriptional suppression of miR-200 family by ZEB1/
ZEB2 is a central contributor to maintaining mesenchymal
characteristics as well as inducing EMT [9]. Here, we show that
P300/PCAF are cofactors for ZEB1 capable of reversing the
ZEB1 suppressive effects on miR-200c/141 transcription and the
important role these miRNA have on determining cell pheno-
type. This is a newly discovered mechanism for miR-200c/141
transcriptional regulation. Also, this data implicates P300/PCAF
in controlling cell phenotypes through regulation of miRNA
expression. In Figure 6, we proposed a model to illustrate how
Figure 5. Changes in miR-200c/141 and P300 result in expected EMT/MET responses. Representative western blot and corresponding real
time PCR analysis shows inhibition of miR200c/141 causes partial EMT shifts in vector cells as evidenced by increased Vimentin, increased ZEB1 and
phenotypic changes. No change is seen in E-cadherin expression. (84 hr post transfection; cells grown on glass coverslips; n$2 independent
experiments) (A). Representative western blot (48 hr) showing partial MET in SPRR2A cells (increased E-cadherin; phenotypic changes on tissues
culture plastic) following transfection with pre-miR-200c and pre-miR-141. Western blot results were verified by real time PCR analysis and
immunofluorescence staining (n = 2 independent experiments) (B). Representative western blot (48 hr) and real time PCR showing changes in EMT
markers following knock down of P300. Phenotypic changes were not observed, but EP300siRNA significantly reduced vector cell miR200c
expression. (n$2 independent experiments) (C) Real time PCR analysis: comparative 22DDCT method (U6 or GAPDH internal control); *, P,0.05; **,
P,0.01; ***, P,0.001; Student’s t-test).
doi:10.1371/journal.pone.0032449.g005
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P300/PCAF controls epithelial/mesenchymal characteristics
through modulating ZEB1 suppression of the miR-200c/141
promoter. To activate miR-141/200c transcription, P300 binds to
PCAF through its CH3 domain, which in turn, facilitates miR-
200c/141 transcription, whereas disruption of the P300-PCAF
(Figure 4E) interaction strongly suppresses the promoter activity.
One mechanism for P300/PCAF activation of miR-200c/141
transcription is through lysine acetylation of ZEB1 (Figure 4B),
which is concordant with the previous report showing that
acetylation of ZEB1 interrupts CtBP binding, and prevents ZEB1
from acting as a transcriptional suppressor. It also explains how
TSA treatment in SPRR2a cells can enhance miR200c/141
expression (Figure 2A). Although TGF-b1 has been shown to
contribute to EMT [32], in HuCCT-1 cells, TGF-b1 did not alter
P300/PCAF/ZEB1 binding on the miR200c promoter (Fig. 4A
and 4D).
Our data verifies P300/PCAF/ZEB1 interactions on the miR-
200c/141 promoter and the importance acetylation plays in
transcriptional regulation of this miRNA. Forced acetylation (via
TSA) and manipulation of P300, PCAF, ZEB1 and SPRR2a
expression (via transfection) can shift miR200c promoter activity
and EMT marker expression. How SPRR2a affects the
interaction of P300/PCAF/ZEB1 followed by EMT or how cells
regulate P300/PCAF itself is still an open question and likely
involves other cofactors yet to be explored. Our findings show a
novel and unifying mechanism for the effect of acetyltransferases
on miRNA transcription and the potential for morphological
consequences.
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